Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Neurology and Therapy
|
March 31, 2023
Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in the United States
Daniel Kantor, Timothy Pham, Oscar Patterson-Lomba, et al.
Postgraduate Medicine
|
January 7, 2015
Assessment of confirmed urinary tract infection in patients treated with dalfampridine for multiple sclerosis
Daniel Kantor, Michael B Chancellor, Clayton W Snell, et al.
Clinical Therapeutics
|
November 8, 2020
Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis
Daniel Kantor, Rina Mehta, Corey Pelletier, et al.
Journal of the Neurological Sciences
|
April 9, 2018
Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis
Daniel Kantor, Kristen Johnson, Maria Cecilia Vieira, et al.
CNS & Neurological Disorders Drug Targets
|
February 28, 2017
Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate
Josephine D Alessandro, Kevin Garofalo, Ganlin Zhao, et al.
Plos One
|
October 17, 2015
Equivalent Gene Expression Profiles between Glatopa™ and Copaxone®
Josephine S D'Alessandro, Jay Duffner, Joel Pradines, et al.
BMC Neurology
|
November 27, 2014
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial
Jonathan Calkwood, Bruce Cree, Heidi Crayton, et al.
Interactive Journal of Medical Research
|
April 29, 2022
Digital Scientific Platform for Independent Content in Neurology: Rigorous Quality Guideline Development and Implementation
Daniel Kantor, Martin Farlow, Albert Ludolph, et al.
The Lancet. Neurology
|
June 24, 2017
Safety and efficacy of dual-lead thalamic deep brain stimulation for patients with treatment-refractory multiple sclerosis tremor: a single-centre, randomised, single-blind, pilot trial
Seth F Oliveria, Ramon L Rodriguez, Dawn Bowers, et al.
Multiple Sclerosis and Related Disorders
|
August 13, 2015
First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis
Bruce Hughes, Mark Cascione, Mark S Freedman, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Neurology and Therapy
|
March 31, 2023
Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in the United States
Daniel Kantor, Timothy Pham, Oscar Patterson-Lomba, et al.
Postgraduate Medicine
|
January 7, 2015
Assessment of confirmed urinary tract infection in patients treated with dalfampridine for multiple sclerosis
Daniel Kantor, Michael B Chancellor, Clayton W Snell, et al.
Clinical Therapeutics
|
November 8, 2020
Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis
Daniel Kantor, Rina Mehta, Corey Pelletier, et al.
Journal of the Neurological Sciences
|
April 9, 2018
Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis
Daniel Kantor, Kristen Johnson, Maria Cecilia Vieira, et al.
CNS & Neurological Disorders Drug Targets
|
February 28, 2017
Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate
Josephine D Alessandro, Kevin Garofalo, Ganlin Zhao, et al.
Plos One
|
October 17, 2015
Equivalent Gene Expression Profiles between Glatopa™ and Copaxone®
Josephine S D'Alessandro, Jay Duffner, Joel Pradines, et al.
BMC Neurology
|
November 27, 2014
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial
Jonathan Calkwood, Bruce Cree, Heidi Crayton, et al.
Interactive Journal of Medical Research
|
April 29, 2022
Digital Scientific Platform for Independent Content in Neurology: Rigorous Quality Guideline Development and Implementation
Daniel Kantor, Martin Farlow, Albert Ludolph, et al.
The Lancet. Neurology
|
June 24, 2017
Safety and efficacy of dual-lead thalamic deep brain stimulation for patients with treatment-refractory multiple sclerosis tremor: a single-centre, randomised, single-blind, pilot trial
Seth F Oliveria, Ramon L Rodriguez, Dawn Bowers, et al.
Multiple Sclerosis and Related Disorders
|
August 13, 2015
First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis
Bruce Hughes, Mark Cascione, Mark S Freedman, et al.
Page
of 3